Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...

The FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in ...

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

Mark Robins has revealed that dipping into the free agent transfer market is not an option for him at Coventry City at this ... club after being released by Bristol City in the summer.

Bristol Myers Squibb (BMY) ended the recent trading session at $48.59, demonstrating a -1.4% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily ...

Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the September 2025 expiration. One of the key data points that goes into the price an option buyer is ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other beaten down dividend stocks. Dividend stocks have faced challenges over the ...